- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Etanercept Effective in Re-Treatment of Juvenile Idiopathic Arthritis: Study
Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease in children and adolescents. A recent study suggests that patients who were re-treated responded well to etanercept in the second treatment course after discontinuing etanercept by inactive disease. The research has been published in the Arthritis Research & Therapy on April 16, 2021.
ETA is the most commonly prescribed biologic disease-modifying anti-rheumatic drugs (bDMARDs) for the treatment of patients with JIA. Studies have shown that ETA has a good treatment response and good tolerability in patients with JIA. However, scant knowledge exists about the disease course and treatment patterns after discontinuation of the first ETA treatment course. Therefore, Dr Jens Klotsche and his team conducted a study to determine (i) correlates for etanercept (ETA) discontinuation after achieving an inactive disease and for the subsequent risk of flare and (ii) to analyze the effectiveness of ETA in the re-treatment after a disease flare.
The researchers used data from two ongoing prospective registries, BiKeR and JuMBO for the analysis. JUMBO is the follow-up to BIKER and follows participants into adulthood. From both registries, the researchers collected individual trajectories of clinical data and outcomes from childhood to adulthood in JIA patients treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) and conventional synthetic DMARDs (csDMARDs). They identified 1724 patients with the first ETA course, 338 with the second and 54 with the third ETA course.
Key findings of the study were:
- Upon analysis, the researchers observed similar rates of discontinuation due to ineffectiveness and adverse events in the first (19.4% and 6.2%), second (18.6% and 5.9%), and third (14.8% and 5.6%) ETA course.
- They noted that overall, 332 patients (+/−methotrexate, 19.3%) discontinued ETA after achieving remission with the first ETA course.
- They found that younger age, persistent oligoarthritis, shorter duration between JIA onset and etanercept start, and a good response to therapy within the first 6 months significantly correlated to discontinuation with inactive disease.
- They observed reoccurrence of active disease in 77% of patients with a mean time to flare of 12.1 months. However, they could not identify any factor correlating to flare risk.
- They noted that the majority of patients after flare were re-treated with ETA (n = 117 of 161).
- Among 117 patients, they noted that 23 patients (one in five patients) discontinued the drug again after achieving an inactive disease, while about 70% achieved an inactive disease 12months after restarting etanercept.
The authors concluded, "The study confirms the effectiveness of ETA even for re-treatment of patients with JIA. Our data highlight the association of an early bDMARD treatment with a higher rate of inactive disease indicating a window of opportunity."
For further information:
https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-021-02492-0
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751